Lymphoma

Low-dose rotational total skin electron beam therapy helped to improve skin-related quality of life and yielded promising responses among patients with mycosis fungoides.

Pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin appears to be a successful bridging regimen for patients with relapsed/refractory classical Hodgkin lymphoma.

Patients with relapsed/refractory Waldenströms macroglobulinemia benefited from treatment with ixazomib, rituximab, and dexamethasone and maintained a tolerable safety profile.

PET-negative patients who are treated with radiotherapy had a slightly increased absolute cardiovascular disease risk, although magnitude of these effects varied widely.

FT596 and FT516 natural killer cell products elicited promising responses in a population of patients with B-cell lymphoma.

Treatment with ibrutinib with or without rituximab was associated with a lower monthly health care cost compared with chemoimmunotherapy in a population of patients with relapsed/refractory mantle cell lymphoma.

Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone helped patients to achieve a significantly improved progression-free survival over the standard of care for previously untreated diffuse large B-cell lymphoma.

The accelerated approval status for romidepsin for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma has been withdrawn following the results of the confirmatory phase 3 Ro-CHOP trial.

Zanubrutinib yielded a high response rate and extended progression-free survival in patients with relapsed/refractory mantle cell lymphoma.

CancerNetwork® speaks with Kami Maddocks, MD, in part 2 of a 3-part series on CD19–directed agents and other second-line agent for relapsed/refractory diffuse large B-cell lymphoma.

Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.

For patients with large B-cell lymphoma who have undergone treatment with axicabtagene ciloleucel, ctDNA monitoring may help to improve early detection of recurrent disease.

Patients with relapsed/refractory mantle cell lymphoma experienced promising response rates after undergoing treatment with zanubrutinib.

An oncology pharmacist talks secondary malignancies noted with tazemetostat in the treatment of follicular lymphoma.

Early-phase data indicate that loncastuximab tesirine-lpyl elicited promising, long-lasting responses in patients with mantle cell lymphoma.

Javier L. Munoz, MD, MS, FACP, discusses how the sequencing of therapies has changed in the last year.

Tazemetostat use only requires dosing modifications in a small percentage of patients, according to an oncology pharmacist.

Adverse effects in patients taking tazemetostat were manageable, with most patients reporting low-grade fatigue, pain, and nausea.

An expert in relapsed/refractory follicular lymphoma discusses the approval of tazemetostat as a treatment and reviews the phase 2 clinical trial data.

Javier L. Munoz, MD, MS, FACP, describes the current third-line treatment options available for relapsed/refractory follicular lymphoma.

An oncology pharmacist details the unique mechanism of active of tazemetostat in the treatment of follicular lymphoma.

A specialist explains the factors considered when it comes to choosing treatments for patients with relapsed/refractory follicular lymphoma, and the clinical endpoints to look for.

Javier L. Munoz, MD, MS, FACP, describes the effects of R/R FL and discusses the current treatment options available.

The FDA granted orelabrutinib breakthrough therapy designation for the treatment of relapsed or refractory mantle cell lymphoma.

Patients in the ZUMA-7 trial who were assigned Yescarta (axicabtagene ciloleucel) saw event-free survival by 60% compared to patients who were on a chemotherapy plus stem cell regimen.